Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

International journal of cancer·2026
Same author

Trends in the incidence and surgical treatment of hepatocellular carcinoma in Ontario.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Corrigendum to "Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study" [Surgery 183 (2025) 109396].

Surgery·2026
Same journal

Directional Bias in Polyp Detection during Colonoscopy: A Prospective Observational Study.

Digestion·2026
Same journal

Prospective validation of magnified endoscopic examination with image-enhanced endoscopy as an optical biopsy for differentiating superficial duodenal epithelial tumor and non-neoplastic lesion in duodenum.

Digestion·2026
Same journal

Accurate imaging diagnosis of small pancreatic carcinoma/high-grade pancreatic intraepithelial neoplasia using combined indirect imaging findings.

Digestion·2026
Same journal

Restoration of gut microbiota dysbiosis by a probiotic Lactobacillus paragasseri OLL2716 in patients being treated with low-dose aspirin and acid-suppressive agents.

Digestion·2026
Same journal

Adverse Events after Colorectal Polypectomy in Patients with Amyloidosis: Risk Assessment Using Propensity Score Matching.

Digestion·2026
Same journal

Prognostic effect of MES 1 inflammatory extent on remission maintenance in ulcerative colitis.

Digestion·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

901

Cholangiocellular Carcinoma.

Arndt Vogel1, Anna Saborowski

  • 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Digestion
|March 14, 2017
PubMed
Summary
This summary is machine-generated.

Cholangiocarcinomas (CCA) are aggressive biliary cancers often diagnosed late. Current treatments include gemcitabine/cisplatin chemotherapy, with future promise in targeted therapies and immunotherapy.

Keywords:
Biliary tract cancerChemotherapyCholangiocarcinomaTargeted therapy

More Related Videos

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

59
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

885

Related Experiment Videos

Last Updated: Mar 6, 2026

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

901
Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

59
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

885

Area of Science:

  • Oncology
  • Gastroenterology
  • Hepatology

Background:

  • Cholangiocarcinomas (CCA) are aggressive biliary tract cancers with intrahepatic and extrahepatic classifications.
  • Risk factors include liver fluke infestation and primary sclerosing cholangitis, though many cases are sporadic.
  • CCA diagnosis often occurs at advanced stages due to a lack of early screening markers.

Purpose of the Study:

  • To review the current landscape of cholangiocarcinoma treatment.
  • To highlight the limitations of existing therapies and the need for further research.
  • To discuss the potential of emerging treatment modalities.

Main Methods:

  • Review of current clinical practice and literature regarding cholangiocarcinoma.
  • Analysis of first-line chemotherapy regimens and their efficacy.
  • Evaluation of the role of loco-regional therapies, targeted treatments, and immunotherapy.

Main Results:

  • Gemcitabine plus cisplatin is the standard first-line palliative chemotherapy for non-resectable CCA, improving survival by 3.6 months over gemcitabine monotherapy.
  • There is a lack of recommended second-line treatment options for patients progressing on first-line chemotherapy.
  • Molecular profiling indicates potential for targeted therapies in specific patient subgroups.

Conclusions:

  • CCA is a genetically diverse and aggressive malignancy requiring novel therapeutic strategies.
  • While gemcitabine-based chemotherapy is standard, further evaluation of loco-regional treatments is needed.
  • Targeted therapies and immunotherapies hold significant promise for improving outcomes in CCA patients.